Department of Gynecology and Endocrinology, FSBSI "The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O.Ott", Saint Petersburg, Russia.
Department of Obstetrics and Gynecology, North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia.
Gynecol Endocrinol. 2020;36(sup1):16-19. doi: 10.1080/09513590.2020.1816722.
Genital endometriosis (GE) is a widespread gynecological disease which requires its further pathogenesis investigation and search for new effective treatments. The known data of oxytocin receptor presence in endometrioid heterotopy smooth muscle cells give some grounds to assume oxytocin participation in the pathogenesis of endometriosis. The present study objective was to evaluate oxytocin level in peripheral blood (PB) in patients with endometriosis associated pain syndrome and to estimate the efficacy of oxytocin receptor inhibitors (IOXTR) administration based on animal endometriosis model.
The basic group comprised 61 patients with endometriosis associated pain syndrome, while 21 patients formed the control group. VAS, MPQ, and BBS objective tests were applied for pain syndrome evaluation. Oxytocin level in PB was measured by immunoenzyme method. After confirmation of endometriosis experimental model formation in rats and further randomization, a daily IOXTR intra-abdominal injection was performed in a dose of 0.35 mg/kg/24 h in the basic group ( = 12) or saline solution administration in the control ( = 12). On the final stage, endometrioid heterotopy size measuring was performed along with histological examination.
Oxytocin level in PB was authentically higher in patients with GE compared to the control: 51.45 (35.54-62.76) pg/mL and 27.64 (23.23-34.12) pg/mL, respectively (<.001). Positive correlation between oxytocin PB level and pain syndrome expression was established in patients with GE: VAS ( = 0.76; <.001), MPQ ( = 0.52; <.001), and BBS ( = 0.57; <.001). Based on the experimental disease model authentical decrease of endometrioid heterotopy average area was observed after IOXTR therapy compared to the control (7.3 ± 1.8 mm and 22.2 ± 1.2 mm, respectively, <.05).
The obtained results confirm the oxytocin role in the pathogenesis of endometrioid associated pain syndrome. The high efficacy of IOXTR administration based on animal model of surgically induced endometriosis allows viewing this method as a perspective therapy.
生殖器子宫内膜异位症（GE）是一种广泛存在的妇科疾病，需要进一步研究其发病机制并寻找新的有效治疗方法。已知催产素受体存在于子宫内膜异位症平滑肌细胞中，这为催产素参与子宫内膜异位症的发病机制提供了一些依据。本研究的目的是评估子宫内膜异位症相关疼痛综合征患者外周血（PB）中的催产素水平，并根据动物子宫内膜异位症模型评估催产素受体抑制剂（IOXTR）的疗效。
基础组包括 61 例子宫内膜异位症相关疼痛综合征患者，对照组包括 21 例患者。采用视觉模拟评分法（VAS）、麦吉尔疼痛问卷（MPQ）和巴氏指数（BBS）进行疼痛综合征评估。采用免疫酶法测定 PB 中催产素水平。在大鼠子宫内膜异位症实验模型形成并进一步随机分组后，基础组每天腹腔内注射 IOXTR 0.35mg/kg/24h（n=12），对照组给予生理盐水（n=12）。在最后阶段，测量子宫内膜异位症异位大小并进行组织学检查。
GE 患者 PB 中的催产素水平明显高于对照组：51.45（35.54-62.76）pg/mL 和 27.64（23.23-34.12）pg/mL（<0.001）。GE 患者 PB 中催产素水平与疼痛综合征表达呈正相关：VAS（r=0.76；<0.001）、MPQ（r=0.52；<0.001）和 BBS（r=0.57；<0.001）。基于实验疾病模型，与对照组相比，IOXTR 治疗后子宫内膜异位症异位平均面积明显减小（分别为 7.3±1.8mm 和 22.2±1.2mm，<0.05）。
研究结果证实了催产素在子宫内膜异位症相关疼痛综合征发病机制中的作用。基于手术诱导子宫内膜异位症动物模型，IOXTR 治疗的高疗效使该方法成为一种有前途的治疗方法。
